Comparative Outcomes of Consolidation Strategies After R‐ MVP Induction in Primary Diffuse Large B‐Cell Lymphoma of the Central Nervous System

作者：Sang‐A Kim, Kim J, Ji Yun Lee, Ji Yun Lee, Joo Ho Lee, Joo Ho Lee, Keun‐Yong Eom, Chul‐Kee Park, Chae‐Yong Kim, Dae Seog Heo, Jeong‐Ok Lee, Jeong‐Ok Lee, Tae Min Kim · 发表于：Cancer Medicine · 年份：2026 · DOI：10.1002/cam4.71806 · 被引用次数：1 · 研究领域：CNS Lymphoma Diagnosis and Treatment、Glioma Diagnosis and Treatment、Lymphoma Diagnosis and Treatment

BACKGROUND: The optimal consolidation strategy following high-dose methotrexate (MTX)-based induction in primary central nervous system lymphoma (PCNSL) remains controversial. This study compared real-world outcomes of different consolidation modalities in patients responsive to rituximab, MTX, vincristine, and procarbazine (R-MVP) induction chemotherapy. METHODS: We retrospectively analyzed 296 newly diagnosed PCNSL patients treated with R-MVP between 2008 and 2023. Among 290 evaluable patients, the overall response rate (ORR) was assessed, and survival outcomes were evaluated by Kaplan-Meier and Cox regression analyses. Propensity score matching (PSM) was performed to compare autologous stem-cell transplantation (ASCT) and whole-brain radiotherapy (WBRT). RESULTS: The ORR was 89.7%, with 71.7% achieving complete response (CR) or complete response unconfirmed (CRu) and 17.9% partial response (PR). Of 260 responders, 190 received consolidation: WBRT (40.8%), ASCT (20.0%), or non-myelosuppressive chemotherapy (NMC; 12.3%). After a median follow-up of 45.3 months, median progression-free survival (PFS) and overall survival (OS) for responders were 65.8 (95% CI 50.7-80.8) and 84.6 months (95% CI 66.5-102.7), respectively. ASCT yielded the most favorable survival (median PFS not reached), followed by WBRT (70.8 months), whereas NMC and no-consolidation groups showed significantly inferior PFS (22.9 and 40.1 months, p < 0.001). OS showed a similar trend (p = 0.006). On multivariab...